By D. Kevin McNeirSpecial to the AFROkmcneir@afro.com
Sickle cell consciousness month, noticed yearly in September, is a time to lift consciousness about sickle cell illness, a genetic blood dysfunction that impacts thousands and thousands of individuals worldwide.
All through the month, medical professionals and nonprofit organizations just like the Sickle Cell Illness Affiliation of America Inc. sponsor occasions that educate the general public, spotlight the challenges confronted by people with the illness, advocate for analysis and coverings and supply assist for sickle cell sufferers and their households.
Traditionally, one remedy for Sickle Cell Illness (SCD) has been a stem cell transplant, often known as a bone marrow transplant. Nevertheless, with medical developments, there are actually totally different remedies for SCD within the type of drug therapies. Nevertheless, they’re intensive and costly procedures, typically carrying with them important dangers, together with the opportunity of dying.
One drug remedy, Oxbryta, developed and launched by Pfizer in 2019 after being authorized by the FDA, has since been withdrawn from the market. However not with out damaging ramifications. And that’s the place LaRuby Might, a former D.C. metropolis council member and legal professional, enters the image.
As a accomplice of Might Jung LLP, she, and her regulation accomplice, Je Yon Jung, are presently representing shoppers who had been handled for SCD with Oxbryta and who proceed to endure in varied methods. The opposite members of her authorized workforce embody Shelby Yarbrough and Starr Culpepper.
“Now we have the outcomes of the medical trials and know that Pfizer voluntarily withdrew the medicine off the market,” Might stated. “As of 2024, they had been going through fees that included negligence, false promoting product deficiencies. There are different claims as properly. Our workforce is dedicated to representing our brothers and sisters who had been harmed by this drug. The science is there – the drug was launched prematurely and has brought about irreparable injury.”
Might stated she nonetheless waits for the day when America’s leaders will do the proper factor on the subject of folks of shade.
“The drug remedy Oxbryta was authorized on an accelerated schedule beneath Donald Trump in 2019,” she stated. “In July 2025, once more beneath Trump, it was taken off the market. On the similar time, the Administration revoked analysis that the NIH was doing to deal with and treatment SCD. I don’t have concrete proof, however it’s actually fairly a coincidence.”
Might added that Blacks folks have, for much too lengthy, lived with well being disparities when in comparison with White folks.
Credit score: Courtesy photograph
“The well being care disparity in America is actual and it’s not getting smaller– however bigger. Black are dying from SCD, HIV/AIDS, hypertension, diabetes–you identify it. There’s an unacceptable hole in nearly each side of well being care and the standard of providers that Blacks obtain,” stated Might. “SCD is only one of many examples. Individuals could also be silent about SCD nevertheless it’s not as a result of they don’t care. They only have a lot with which they have to contend that it’s generally overwhelming”
Might stated her workforce is “in it to win it.”
“One among our workforce members, Starr, has a daughter with SCD, so that is private to her,” Might stated. “I imagine we’ve assembled a strong workforce. We’re holding Pfizer accountable to their company duties and are demanding that they put cash into credible analysis that can result in a treatment for SCD.
“Black are bored with getting used as check dummies with out giving our permission. That’s why we regularly fail to turn into concerned in medical trials – we don’t belief the scientific group,” stated Might. “However to discover a treatment, we’d like extra Blacks to turn into concerned in medical trials. For that to occur, drug corporations and medical professionals are going to must be clear and trustworthy.” For those who or a cherished one has sickle cell illness and you’ve got taken the medicine Oxbryta, chances are you’ll be eligible for compensation. Contact LaRuby Might at (202) 869-3735, or e-mail: laruby@mayjung.com.
